FDA Blasted Over Shared Risk Plans For Brand, Generic Cos.
The U.S. Food and Drug Administration has left pharmaceutical companies exposed to antitrust enforcement and product liability suits by failing to explain clearly how brand-name drugmakers and generics companies can negotiate...To view the full article, register now.
Already a subscriber? Click here to view full article